Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic Cholangiocarcinoma

Table 2

Treatment characteristics and cumulative toxicities analysis: only Grade 3-4 toxicities are reported (CTCAE version 4.0).

Treatment characteristics	HDR-BT	RE	RFA	TACE	ivCTX	iaCTX
Patients (n)	45	11	3	3	16	9
Karnofsky index,; median (range)	80; (60–100)	80; (60–90)	90; (60–90)	70; (70)	70; (60–100)	90; (80–90)
ECOG index,; median (range)	1; (0–2)	1; (0–2)	0; (0–2)	1; (1-1)	1; (0–2)	0; (0-1)
Number of days hospitalized, median (range)	4; (1–11)	4; (3–5)	5; (4–6)	4; (3–6)	0	0
Total number of treatments/chemotherapeutic cycles (n)	101	20	3	12	64	43
Median number of treatments/chemotherapeutic cycles per patient (range)	1; (1–5)	1; (1–4)	3; (1-1)	4; (3–5)	5; (1–12)	6; (4–23)
Median RE-dose delivered (GBq), median (range)	—	1.63; (0.9–2.55)	—	—	—	—
Best response	CR	PR	CR	PD	SD	PR
Adverse events acc. CTCAE (highest grade recorded)	3	2	2	1	3	2
Abscess (n)	1	—	—	—	—	—
Shivering (n)	1	—	—	—	—	—
Hematoma subcapsular (n)	1	—	—	—	—	—
Anemia (n)	—	—	—	—	1	—
Thrombopenia (n)	—	—	—	—	1	—
Neutropenia (n)	—	—	—	—	1	—
Anorexia (n)	—	—	—	—	1	—
Fatigue (n)	—	—	—	—	2	—
Pain (n)	—	—	—	—	1	—
Diarrhea (n)	—	—	—	—	1	—
Rash (n)	—	—	—	—	1	—

Data are expressed as absolute number of events (n).
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. CTCAE, common toxicity criteria of adverse events.
Shivering due to radiation effects during HDR-BT with the need for abruption of the intervention.